Cocrystal structures of primed side-extending α-ketoamide inhibitors reveal novel calpain-inhibitor aromatic interactions

Journal of Medicinal Chemistry

Volumn 51, Issue 17, 2008, Pages 5264-5270

  Qian, Jin ^a   Cuerrier, Dominic ^a,c   Davies, Peter L ^a   Li, Zhaozhao ^b   Powers, James C ^b   Campbell, Robert L ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c Cytochroma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (BENZYLOXYCARBONYLLEUCYLAMINO) N [3 (4 METHYLPIPERAZIN 1 YL)PROPYL] 2 OXOPENTANAMIDE; 3 (BENZYLOXYCARBONYLLEUCYLAMINO) N [3 (6 AMINO 9H PURIN 9 YL)PROPYL] 2 OXOPENTANAMIDE; CALPAIN; CALPASTATIN; CYSTEINE PROTEINASE; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG MECHANISM; NONHUMAN; RAT; STRUCTURE ANALYSIS;

AMINO ACIDS, AROMATIC; ANIMALS; CALPAIN; CARBAMATES; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; GLYCOPROTEINS; PROTEIN CONFORMATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 51849085222     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800045t     Document Type: Article

References (38)

1. Goll, D. E.; Thompson, V. F.; Li, H.; Wei, W.; Cong, J. The calpain system. Physiol. Rev. 2003, 83, 731-801.
2. Carragher, N. O. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr. Pharm. Des. 2006, 12, 615-638.
3. Wang, K. K.; Yuen, P. W. Development and therapeutic potential of calpain inhibitors. Adv. Pharmacol. 1997, 37, 117-152.
4. Sorimachi, H.; Suzuki, K. The structure of calpain. J. Biochem. (Tokyo) 2001, 129, 653-664.
5. 2+-dependent protease activity and a novel mode of enzyme activation. EMBO J. 1999, 18, 6880-6889.
6. 2+ binding at two non-EF-hand sites. J. Biol. Chem. 2004, 279, 6106-6114.
7. Pal, G. P.; Elce, J. S.; Jia, Z. Dissociation and aggregation of calpain in the presence of calcium. J. Biol. Chem. 2001, 276, 47233-47238.
8. 2+ switch aligns the active site of calpain. Cell 2002, 108, 649-660.
9. Neffe, A. T.; Abell, A. D. Developments in the design and synthesis of calpain inhibitors. Curr. Opin. Drug Discovery Dev. 2005, 8, 684-700.
10. Davis, T. L.; Walker, J. R., Jr.; Mackenzie, F.; Newman, E. M.; Dhe-Paganon, S. The crystal structures of human calpains 1 and 9 imply diverse mechanisms of action and auto-inhibition. J. Mol. Biol. 2007, 366, 216-229.
11. Li, Q.; Hanzlik, R. P.; Weaver, R. F.; Schonbrunn, E. Molecular mode of action of a covalently inhibiting peptidomimetic on the human calpain protease core. Biochemistry 2006, 45, 701-708.
12. Donkor, I. O. A survey of calpain inhibitors. Curr. Med. Chem. 2000, 7, 1171-1188.
13. Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 2002, 102, 4639-4750.
14. Cuerrier, D.; Moldoveanu, T.; Davies, P. L. Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions. J. Biol. Chem. 2005, 280, 40632-40641.
15. Cuerrier, D.; Moldoveanu, T.; Inoue, J.; Davies, P. L.; Campbell, R. L. Calpain inhibition by alpha-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography. Biochemistry 2006, 45, 7446-7452.
16. Choe, Y.; Leonetti, F.; Greenbaum, D. C.; Lecaille, F.; Bogyo, M.; Bromme, D.; Ellman, J. A.; Craik, C. S. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem. 2006, 281, 12824-12832.
17. Li, Z.; Paul, G. S.; Golubski, Z. E.; Hori, H.; Tehrani, K.; Foreman, J. E.; Eveleth, D. D.; Bartus, R. T; Powers, J. C. Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1993, 36, 3472-3480.
18. Chatterjee, S.; Dunn, D.; Tao, M.; Wells, G.; Gu, Z. Q.; Bihovsky, R.; Ator, M. A.; Siman, R.; Mallamo, J. P. P2-achiral, P′-extended alpha-ketoamide inhibitors of calpain I. Bioorg. Med. Chem. Lett. 1999, 92371-2374.
19. Donkor, I. O.; Han, J; Zheng, X. Design, synthesis, molecular modeling studies, and calpain inhibitory activity of novel alpha-ketoamides incorporating polar residues at the P1′-position. J. Med. Chem. 2004, 47, 72-79.
20. Moldoveanu, T.; Campbell, R. L.; Cuerrier, D.; Davies, P. L. Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. J. Mol. Biol. 2004, 343, 1313-1326.
21. Ohndorf, U. M.; Rould, M. A.; He, Q.; Pabo, C. O.; Lippard, S. J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999, 399, 708-712.
22. Valegard, K.; Murray, J. B.; Stonehouse, N. J.; van den Worm, S.; Stockley, P. G.; Liljas, L. The three-dimensional structures of two complexes between recombinant MS2 capsids and RNA operator fragments reveal sequence-specific protein-RNA interactions. J. Mol. Biol. 1997, 270, 724-738.
23. Oubridge, C.; Ito, N.; Evans, P. R.; Teo, C. H.; Nagai, K. Crystal structure at 1.92 Å resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin. Nature 1994, 372, 432-438.
24. Price, S. R.; Evans, P. R.; Nagal, K. Crystal structure of the spliceosomal U2B″-U2A′ protein complex bound to a fragment of U2 small nuclear RNA. Nature 1998, 394, 645-650.
25. Handa, N.; Nureki, O.; Kurimoto, K.; Kim, I.; Sakamoto, H.; Shimura, Y.; Muto, Y.; Yokoyama, S. Structural basis for recognition of the tra mRNA precursor by the Sex-lethal protein. Nature 1999, 398, 579-585.
26. Nolan, S. J.; Shiels, J. C.; Tuite, J. B.; Cecere, K. L.; Baranger, A. M. Recognition of an essential adenine at a protein-RNA interface: comparison of the contributions of hydrogen bonds and a stacking arrangement. J. Am. Chem. Soc. 1999, 121, 8951-8952.
27. Rutledge, L. R.; Campbell-Verduyn, L. S.; Hunter, K. C.; Wetmore, S. D. Characterization of nucleobase-amino acid stacking interactions utilized by a DNA repair enzyme. J. Phys. Chem. B 2006, 110, 19652-19663.
28. David, S. S.; O'Shea, V. L.; Kundu, S. Base-excision repair of oxidative DNA damage. Nature 2007, 447, 941-950.
29. 2+-induced structural changes in rat m-calpain revealed by partial proteolysis. Biochim. Biophys. Acta 2001, 1545, 245-254.
30. Li, Z.; Ortega-Vilain, A.-C.; Patil, G. S.; Chu, D.- L.; Foreman, J. E.; Eveleth, D. D.; Powers, J. C. Novel peptidyl α-keto amide inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1996, 39, 4089-4098.
31. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 ESF-EAMCB Newsl. Protein Crystallogr. 1992 26.
32. Evans, P. R. Scaling and assessment of data quality. Acta Crystallogr.: Sect. D: Biol. Crystallogr. 2006, 62, 72-82.
33. Collaborative computational project, number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
34. Vagin, A. T.; Teplyakov, A. An automated program for molecular replacement. J Appl. Crystallogr. 1997, 30, 1022-1025.
35. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363.
36. Murshudov, G. N.; Vagin, A. A.; Lebedev, A.; Wilson, K. S.; Dodson, E. J. Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr., Sect. D: Biol. Crystallogr 1999, 55, 247-255.
37. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
38. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: Palo Alto, CA, 2003; http://www.pymol.org.